Thermo Fisher and OpenAI are embedding AI across clinical trials work at PPD to shorten trial cycle times.

Thermo Fisher announced a collaboration to deploy OpenAI capabilities first in its PPD clinical research business, to improve clinical trial cycle times. The AI is also being integrated into its Accelerator Drug Development solution (early development through commercialization), and ChatGPT Enterprise is being rolled out to employees. The announcement gives no quantified results.

Thermo Fisher Scientific is a life sciences tools and services giant whose software, LIMS and PPD clinical research arm are adding AI across labs and clinical trials.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.